The emerging role of FTY720 (Fingolimod) in cancer treatment

Christopher White; Heba Alshaker; Colin Cooper; Matthias Winkler; Dmitri Pchejetski

doi:10.18632/oncotarget.7145

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

The emerging role of FTY720 (Fingolimod) in cancer treatment

Christopher White _, Heba Alshaker, Colin Cooper, Matthias Winkler and Dmitri Pchejetski

PDF | HTML | How to cite

Oncotarget. 2016; 7:23106-23127. https://doi.org/10.18632/oncotarget.7145

Metrics: PDF 3550 views | HTML 7377 views | ?

Abstract

Christopher White1,*, Heba Alshaker2,3,*, Colin Cooper3, Matthias Winkler4 and Dmitri Pchejetski3

1 School of Medicine, Imperial College London, London, UK

2 Department of Pharmacology and Biomedical Sciences, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, Jordan

3 School of Medicine, University of East Anglia, Norwich, UK

4 Department of Surgery and Cancer, Imperial College London, London, UK

* These authors have contributed equally to this work

Correspondence to:

Christopher White, email:

Heba Alshaker, email:

Keywords: sphingolipid, sphingosine kinase, fingolimod, FTY720, cancer

Received: August 29, 2015 Accepted: January 19, 2016 Published: February 02, 2016

Abstract

FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple sclerosis that sequesters T-cells to lymph nodes through functional antagonism of sphingosine-1-phosphate 1 receptor. FTY720 also demonstrates a proven efficacy in multiple in vitro and in vivo cancer models, suggesting a potential therapeutic role in cancer patients. A potential anticancer mechanism of FTY720 is through the inhibition of sphingosine kinase 1, a proto-oncogene with in vitro and clinical cancer association. In addition, FTY720’s anticancer properties may be attributable to actions on several other molecular targets. This study focuses on reviewing the emerging evidence regarding the anticancer properties and molecular targets of FTY720. While the clinical transition of FTY720 is currently limited by its immune suppression effects, studies aiming at FTY720 delivery and release together with identifying its key synergetic combinations and relevant patient subsets may lead to its rapid introduction into the clinic.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7145

Publication Alerts

Reviews:

The emerging role of FTY720 (Fingolimod) in cancer treatment

Abstract